SG11201901697QA - Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof - Google Patents
Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereofInfo
- Publication number
- SG11201901697QA SG11201901697QA SG11201901697QA SG11201901697QA SG11201901697QA SG 11201901697Q A SG11201901697Q A SG 11201901697QA SG 11201901697Q A SG11201901697Q A SG 11201901697QA SG 11201901697Q A SG11201901697Q A SG 11201901697QA SG 11201901697Q A SG11201901697Q A SG 11201901697QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- methods
- pct
- rule
- channelopsin
- Prior art date
Links
- 206010034960 Photophobia Diseases 0.000 title abstract 2
- 208000013469 light sensitivity Diseases 0.000 title abstract 2
- 230000035772 mutation Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 241001071861 Lethrinus genivittatus Species 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000016732 phototransduction Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Neurology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380871P | 2016-08-29 | 2016-08-29 | |
| PCT/US2017/049158 WO2018044912A1 (en) | 2016-08-29 | 2017-08-29 | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901697QA true SG11201901697QA (en) | 2019-03-28 |
Family
ID=59859616
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202102061SA SG10202102061SA (en) | 2016-08-29 | 2017-08-29 | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |
| SG11201901697QA SG11201901697QA (en) | 2016-08-29 | 2017-08-29 | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202102061SA SG10202102061SA (en) | 2016-08-29 | 2017-08-29 | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11041004B2 (ko) |
| EP (1) | EP3504227A1 (ko) |
| JP (1) | JP7116884B2 (ko) |
| KR (2) | KR20230169427A (ko) |
| CN (1) | CN110023327B (ko) |
| AU (3) | AU2017319306B2 (ko) |
| BR (1) | BR112019003950A2 (ko) |
| CA (1) | CA3034887A1 (ko) |
| IL (2) | IL310142A (ko) |
| MX (1) | MX2019002321A (ko) |
| MY (1) | MY197491A (ko) |
| RU (1) | RU2019109021A (ko) |
| SG (2) | SG10202102061SA (ko) |
| WO (1) | WO2018044912A1 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3504227A1 (en) | 2016-08-29 | 2019-07-03 | Wayne State University | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |
| CN113173984B (zh) * | 2021-04-12 | 2022-08-30 | 中眸医疗科技(武汉)有限公司 | 一种新型光敏感通道蛋白vr1.0在制备视网膜感光细胞退行性疾病药物中的应用 |
| CN117858894A (zh) * | 2021-12-20 | 2024-04-09 | 健达九州(北京)生物科技有限公司 | 用光敏性gq偶联神经视蛋白(视蛋白5)的光遗传学视觉恢复 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| WO1992008796A1 (en) | 1990-11-13 | 1992-05-29 | Immunex Corporation | Bifunctional selectable fusion genes |
| WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| CA2183667A1 (en) | 1994-02-22 | 1995-08-24 | Wayne A. Marasco | Nucleic acid delivery system, method of synthesis and uses thereof |
| EP2465925A1 (en) | 2005-07-22 | 2012-06-20 | The Board Of Trustees Of The Leland | Light-activated cation channel and uses thereof |
| CN101484005A (zh) | 2006-05-04 | 2009-07-15 | 韦恩州立大学 | 通过向体内递送视紫红质核酸恢复视觉响应 |
| US20100008170A1 (en) | 2006-06-27 | 2010-01-14 | Shinya Sato | Semiconductor tester and testing method of semiconductor memory |
| ES2801679T3 (es) | 2011-11-12 | 2021-01-12 | Massachusetts Inst Technology | Canalrodopsinas para el control óptico de células |
| EP2822964B1 (en) | 2012-03-05 | 2018-08-22 | Wayne State University | Identification of channelrhodopsin-2 (chop2) mutations and methods of use |
| EP2968476B1 (en) * | 2013-03-14 | 2021-05-05 | Wayne State University | A plasmin for use in enhancing delivery of therapeutic compounds to the eyes or for improving vision |
| WO2015167639A1 (en) | 2014-02-07 | 2015-11-05 | Massachusetts Institute Of Technology | Blue light-activated ion channel molecules and uses thereof |
| US10590181B2 (en) | 2014-04-18 | 2020-03-17 | Massachusetts Institute Of Technology | Mutant channelrhodopsins with altered ion selectivity |
| US11324824B2 (en) * | 2016-06-03 | 2022-05-10 | Massachusetts Institute Of Technology | Somatic opsins for single cell resolution optogenetics |
| EP3504227A1 (en) | 2016-08-29 | 2019-07-03 | Wayne State University | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |
-
2017
- 2017-08-29 EP EP17767952.9A patent/EP3504227A1/en active Pending
- 2017-08-29 SG SG10202102061SA patent/SG10202102061SA/en unknown
- 2017-08-29 CA CA3034887A patent/CA3034887A1/en active Pending
- 2017-08-29 IL IL310142A patent/IL310142A/en unknown
- 2017-08-29 JP JP2019531572A patent/JP7116884B2/ja active Active
- 2017-08-29 KR KR1020237041296A patent/KR20230169427A/ko active Search and Examination
- 2017-08-29 KR KR1020197008895A patent/KR102609571B1/ko active IP Right Grant
- 2017-08-29 MY MYPI2019001044A patent/MY197491A/en unknown
- 2017-08-29 US US16/328,916 patent/US11041004B2/en active Active
- 2017-08-29 RU RU2019109021A patent/RU2019109021A/ru unknown
- 2017-08-29 CN CN201780060143.3A patent/CN110023327B/zh active Active
- 2017-08-29 SG SG11201901697QA patent/SG11201901697QA/en unknown
- 2017-08-29 IL IL265010A patent/IL265010B1/en unknown
- 2017-08-29 AU AU2017319306A patent/AU2017319306B2/en active Active
- 2017-08-29 BR BR112019003950A patent/BR112019003950A2/pt unknown
- 2017-08-29 WO PCT/US2017/049158 patent/WO2018044912A1/en unknown
- 2017-08-29 MX MX2019002321A patent/MX2019002321A/es unknown
-
2021
- 2021-05-19 US US17/324,501 patent/US20220089660A1/en active Pending
-
2022
- 2022-02-25 AU AU2022201291A patent/AU2022201291B2/en active Active
-
2024
- 2024-01-02 AU AU2024200016A patent/AU2024200016A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022201291B2 (en) | 2023-10-05 |
| IL310142A (en) | 2024-03-01 |
| MY197491A (en) | 2023-06-19 |
| KR20230169427A (ko) | 2023-12-15 |
| MX2019002321A (es) | 2019-10-21 |
| US20220089660A1 (en) | 2022-03-24 |
| KR20190075906A (ko) | 2019-07-01 |
| JP2019528781A (ja) | 2019-10-17 |
| AU2017319306B2 (en) | 2021-12-02 |
| CN110023327B (zh) | 2024-02-27 |
| CA3034887A1 (en) | 2018-03-08 |
| KR102609571B1 (ko) | 2023-12-01 |
| AU2024200016A1 (en) | 2024-01-25 |
| BR112019003950A2 (pt) | 2019-06-25 |
| IL265010B1 (en) | 2024-02-01 |
| AU2022201291A1 (en) | 2022-03-17 |
| WO2018044912A1 (en) | 2018-03-08 |
| JP7116884B2 (ja) | 2022-08-12 |
| EP3504227A1 (en) | 2019-07-03 |
| SG10202102061SA (en) | 2021-04-29 |
| IL265010A (ko) | 2019-04-30 |
| RU2019109021A (ru) | 2020-09-29 |
| RU2019109021A3 (ko) | 2021-02-02 |
| AU2017319306A1 (en) | 2019-04-11 |
| CN110023327A (zh) | 2019-07-16 |
| US20190241628A1 (en) | 2019-08-08 |
| US11041004B2 (en) | 2021-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201810162PA (en) | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201804443UA (en) | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome | |
| SG11201811643TA (en) | Compounds and methods for modulating rna function | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201808830YA (en) | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
| SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201810561YA (en) | Liquid neurotoxin formulation stabilized with tryptophan or tyrosine | |
| SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201408761VA (en) | Purification of iduronate-2-sulfatase | |
| SG11201901697QA (en) | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |